| Year |
Citation |
Score |
| 2023 |
Mountoufaris G, Nair A, Yang B, Kim DW, Anderson DJ. Neuropeptide Signaling is Required to Implement a Line Attractor Encoding a Persistent Internal Behavioral State. Biorxiv : the Preprint Server For Biology. PMID 37961374 DOI: 10.1101/2023.11.01.565073 |
0.653 |
|
| 2021 |
Liu M, Kim DW, Zeng H, Anderson DJ. Make war not love: The neural substrate underlying a state-dependent switch in female social behavior. Neuron. PMID 34982958 DOI: 10.1016/j.neuron.2021.12.002 |
0.588 |
|
| 2019 |
Kim DW, Yao Z, Graybuck LT, Kim TK, Nguyen TN, Smith KA, Fong O, Yi L, Koulena N, Pierson N, Shah S, Lo L, Pool AH, Oka Y, Pachter L, et al. Multimodal Analysis of Cell Types in a Hypothalamic Node Controlling Social Behavior. Cell. 179: 713-728.e17. PMID 31626771 DOI: 10.1016/J.Cell.2019.09.020 |
0.5 |
|
| 2019 |
Lo L, Yao S, Kim DW, Cetin A, Harris J, Zeng H, Anderson DJ, Weissbourd B. Connectional architecture of a mouse hypothalamic circuit node controlling social behavior. Proceedings of the National Academy of Sciences of the United States of America. PMID 30898882 DOI: 10.1073/Pnas.1817503116 |
0.489 |
|
| 2014 |
Hong W, Kim DW, Anderson DJ. Antagonistic control of social versus repetitive self-grooming behaviors by separable amygdala neuronal subsets. Cell. 158: 1348-61. PMID 25215491 DOI: 10.1016/J.Cell.2014.07.049 |
0.611 |
|
| 2014 |
Lee H, Kim DW, Remedios R, Anthony TE, Chang A, Madisen L, Zeng H, Anderson DJ. Scalable control of mounting and attack by Esr1+ neurons in the ventromedial hypothalamus. Nature. 509: 627-32. PMID 24739975 DOI: 10.1038/Nature13169 |
0.635 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2011 |
Lee M, Kim D, Shin HS, Sung HG, Choi JH. High-density EEG recordings of the freely moving mice using polyimide-based microelectrode. Journal of Visualized Experiments : Jove. PMID 21248705 DOI: 10.3791/2562 |
0.27 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2008 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, ... Kim DW, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 3392-7. PMID 18305158 DOI: 10.1073/Pnas.0712359105 |
0.239 |
|
| 2011 |
Kim D, Kwon Y, Park Q, Kim S. Analysis of a head-mounted display-type multifocus display system using a laser scanning method Optical Engineering. 50: 34006. DOI: 10.1117/1.3554376 |
0.236 |
|
| 2015 |
Kim D, Hwang E, Lee M, Sung H, Choi JH. Characterization of topographically specific sleep spindles in mice. Sleep. 38: 85-96. PMID 25325451 DOI: 10.5665/Sleep.4330 |
0.235 |
|
| 2023 |
Noh K, Cho WH, Lee BH, Kim DW, Kim YS, Park K, Hwang M, Barcelon E, Cho YK, Lee CJ, Yoon BE, Choi SY, Park HY, Jun SB, Lee SJ. Cortical astrocytes modulate dominance behavior in male mice by regulating synaptic excitatory and inhibitory balance. Nature Neuroscience. PMID 37563296 DOI: 10.1038/s41593-023-01406-4 |
0.225 |
|
| 2002 |
Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. The European Journal of Neuroscience. 16: 1829-38. PMID 12453046 DOI: 10.1046/J.1460-9568.2002.02255.X |
0.22 |
|
| 2002 |
Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. The European Journal of Neuroscience. 16: 1829-38. PMID 12453046 DOI: 10.1046/J.1460-9568.2002.02255.X |
0.22 |
|
| 2002 |
Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. The European Journal of Neuroscience. 16: 1829-38. PMID 12453046 DOI: 10.1046/J.1460-9568.2002.02255.X |
0.22 |
|
| 2002 |
Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. The European Journal of Neuroscience. 16: 1829-38. PMID 12453046 DOI: 10.1046/J.1460-9568.2002.02255.X |
0.22 |
|
| 2019 |
Park S, Yoo JE, Lee DR, Jang J, Cho MS, Kim DS, Kim DW. Establishment of PITX3-mCherry knock-in reporter human embryonic stem cell line (WAe009-A-23). Stem Cell Research. 39: 101499. PMID 31352199 DOI: 10.1016/J.Scr.2019.101499 |
0.218 |
|
| 2006 |
Kim DW, Chung S, Hwang M, Ferree A, Tsai HC, Park JJ, Chung S, Nam TS, Kang UJ, Isacson O, Kim KS. Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells (Dayton, Ohio). 24: 557-67. PMID 16123386 DOI: 10.1634/Stemcells.2005-0233 |
0.217 |
|
| 2015 |
Lim MS, Chang MY, Kim SM, Yi SH, Suh-Kim H, Jung SJ, Kim MJ, Kim JH, Lee YS, Lee SY, Kim DW, Lee SH, Park CH. Generation of Dopamine Neurons from Rodent Fibroblasts through the Expandable Neural Precursor Cell Stage. The Journal of Biological Chemistry. 290: 17401-14. PMID 26023233 DOI: 10.1074/Jbc.M114.629808 |
0.211 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2008 |
Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale Nature Protocols. 3: 1888-1894. PMID 19008875 DOI: 10.1038/nprot.2008.188 |
0.209 |
|
| 2018 |
Kim JY, Lee JS, Hwang HS, Lee DR, Park CY, Jung SJ, You YR, Kim DS, Kim DW. Wnt signal activation induces midbrain specification through direct binding of the beta-catenin/TCF4 complex to the EN1 promoter in human pluripotent stem cells. Experimental & Molecular Medicine. 50: 24. PMID 29650976 DOI: 10.1038/S12276-018-0044-Y |
0.197 |
|
| 2008 |
Kim SK, Kim DW, Kwon YM, Son JY. Evaluation of the monocular depth cue in 3D displays. Optics Express. 16: 21415-22. PMID 19104571 DOI: 10.1364/Oe.16.021415 |
0.194 |
|
| 2006 |
Cho YH, Kim DS, Kim PG, Hwang YS, Cho MS, Moon SY, Kim DW, Chang JW. Dopamine neurons derived from embryonic stem cells efficiently induce behavioral recovery in a Parkinsonian rat model. Biochemical and Biophysical Research Communications. 341: 6-12. PMID 16412382 DOI: 10.1016/j.bbrc.2005.12.140 |
0.193 |
|
| 2010 |
Kim DW, Kim KB, Kim JY, Lee KS, Seo SB. Negative regulation of neuronal cell differentiation by INHAT subunit SET/TAF-Iβ. Biochemical and Biophysical Research Communications. 400: 419-25. PMID 20800572 DOI: 10.1016/j.bbrc.2010.08.093 |
0.19 |
|
| 2006 |
Hermann A, Maisel M, Wegner F, Liebau S, Kim DW, Gerlach M, Schwarz J, Kim KS, Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells (Dayton, Ohio). 24: 949-64. PMID 16373695 DOI: 10.1634/Stemcells.2005-0192 |
0.187 |
|
| 2004 |
Kim DW. Efficient induction of dopaminergic neurons from embryonic stem cells for application to Parkinson's disease. Yonsei Medical Journal. 23-7. PMID 15250046 DOI: 10.3349/ymj.2004.45.Suppl.23 |
0.187 |
|
| 2023 |
Yeon GB, Jeon BM, Yoo SH, Kim D, Oh SS, Park S, Shin WH, Kim HW, Na D, Kim DW, Kim DS. Differentiation of astrocytes with characteristics of ventral midbrain from human embryonic stem cells. Stem Cell Reviews and Reports. PMID 37067644 DOI: 10.1007/s12015-023-10536-y |
0.171 |
|
| 2022 |
Lee BH, Shim JY, Moon HC, Kim DW, Kim J, Yook JS, Kim J, Park HY. Real-time visualization of mRNA synthesis during memory formation in live mice. Proceedings of the National Academy of Sciences of the United States of America. 119: e2117076119. PMID 35776545 DOI: 10.1073/pnas.2117076119 |
0.168 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2007 |
Kim D, Kim JY, Kang M, Cho MS, Kim D. Derivation of Functional Dopamine Neurons from Embryonic Stem Cells Cell Transplantation. 16: 117-123. DOI: 10.3727/000000007783464650 |
0.165 |
|
| 2003 |
Noh HS, Kim YS, Lee HP, Chung KM, Kim DW, Kang SS, Cho GJ, Choi WS. The protective effect of a ketogenic diet on kainic acid-induced hippocampal cell death in the male ICR mice. Epilepsy Research. 53: 119-28. PMID 12576173 DOI: 10.1016/s0920-1211(02)00262-0 |
0.159 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2011 |
Shin S, Yahng S, Lee S, Cho B, Eom K, Kim Y, Kim H, Lee S, Min C, Cho S, Kim D, Min W, Park C, Lee J. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia, Blood. 118: 3430-3430. DOI: 10.1182/blood.V118.21.3430.3430 |
0.154 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2013 |
Yoon J, Lee S, Kim H, Kim J, Jeon Y, Shin S, Lee S, Eom K, Kim Y, Min C, Cho S, Kim D, Min W, Park C, Lee J. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population Blood. 122: 3345-3345. DOI: 10.1182/blood.v122.21.3345.3345 |
0.152 |
|
| 2003 |
Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY, Kim CC. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 102: 3068-70. PMID 12842984 DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2003 |
Lee S, Kim D, Kim Y, Chung N, Kim Y, Hwang J, Kim C. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia Blood. 102: 3068-3070. DOI: 10.1182/blood-2003-04-1180 |
0.152 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Eom K, Kim H, Cho B, Lee S, Yahng S, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Park C, Min W. Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation. Blood. 116: 4559-4559. DOI: 10.1182/blood.v116.21.4559.4559 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2010 |
Min C, Eom HS, Cho BS, Kim Y, Kim H, Lee S, Cho S, Kim D, Lee JW, Min W, Park C. Survival Impact of Response with Bortezomib Induction on Myeloma Patients Receiving Autologous Stem Cell Transplantation. Blood. 116: 4590-4590. DOI: 10.1182/blood.v116.21.4590.4590 |
0.15 |
|
| 2017 |
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017747162. PMID 29091516 DOI: 10.1200/JCO.2017.74.7162 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2012 |
Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brümmendorf TH, Kim D, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. Blood. 120: 2793-2793. DOI: 10.1182/blood.V120.21.2793.2793 |
0.148 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2015 |
Yoon J, Kim H, Cho BS, Yahng S, Shin S, Lee S, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL) Blood. 126: 3842-3842. DOI: 10.1182/blood.V126.23.3842.3842 |
0.147 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2011 |
Yahng S, Kim Y, Yoon J, Shin S, Lee S, Cho B, Eom K, Lee S, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park C. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS Blood. 118: 2034-2034. DOI: 10.1182/blood.v118.21.2034.2034 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2010 |
Goh H, Kim D, Choi S, Kim S, Lee J, Lee Y, Oh S, Kim D. Impact of Baseline BCR-ABL Transcript Levels on the Response to Imatinib In CP CML Patients Blood. 116: 1240-1240. DOI: 10.1182/blood.v116.21.1240.1240 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2015 |
Yoon J, Kim H, Jeon Y, Yahng S, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Kim D, Lee J, Min W. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types? Blood. 126: 4366-4366. DOI: 10.1182/blood.v126.23.4366.4366 |
0.146 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| 2006 |
Lee S, Cho B, Kim S, Eom K, Kim Y, Min C, Kim H, Cho S, Kim D, Lee J, Min W, Park J, Kim C. Allogeneic Stem Cell Transplantation Should Be Performed in First Complete Remission in Adults with Acute Lymphoblastic Leukemia; Strong Antileukemic Activity of Chronic Graft-Versus-Host Disease. Blood. 108: 2992-2992. DOI: 10.1182/blood.v108.11.2992.2992 |
0.145 |
|
| Hide low-probability matches. |